Tommy Thompson Sells 910 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Tommy Thompson sold 910 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $500.59, for a total transaction of $455,536.90. Following the completion of the sale, the director directly owned 8,480 shares of the company’s stock, valued at $4,245,003.20. This represents a 9.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $517.13 on Friday. The company has a market capitalization of $22.27 billion, a P/E ratio of 19.60, a P/E/G ratio of 5.13 and a beta of 0.86. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $518.61. The firm’s 50 day simple moving average is $463.63 and its two-hundred day simple moving average is $380.95.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the firm earned $6.39 EPS. The company’s revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on UTHR shares. Morgan Stanley set a $447.00 target price on United Therapeutics in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. HC Wainwright upped their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently bought and sold shares of the business. Clearstead Advisors LLC grew its stake in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares in the last quarter. Bessemer Group Inc. grew its position in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares in the last quarter. Archer Investment Corp increased its stake in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 31 shares during the last quarter. F m Investments LLC raised its position in United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 33 shares during the period. Finally, HB Wealth Management LLC lifted its stake in shares of United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.